Core Insights - TPG RE Finance Trust (TRTX) is currently trading at a significant double-digit discount to its book value per share, indicating potential undervaluation in the market [1] - The preferred shares of TRTX are offering elevated yields compared to their levels from a year ago, suggesting an attractive income opportunity for investors [1] - The Federal Reserve is anticipated to further cut interest rates, which may positively impact the performance of REITs and other income-generating assets [1] Company Focus - Pacifica Yield is focused on long-term wealth creation by targeting undervalued yet high-growth companies, high-dividend stocks, REITs, and firms in the green energy sector [1]

Core Viewpoint - TPG RE Finance Trust, Inc. reported strong third-quarter results, highlighting continued investment momentum and a robust loan pipeline that is expected to drive future growth in earnings [2][3]. Financial Performance - The company recognized GAAP net income of $18.4 million, or $0.23 per common share, for the third quarter of 2025, with a book value per common share of $11.25, up from $11.20 at the end of the previous quarter [3]. - Distributable Earnings for the quarter were $19.9 million, or $0.25 per common share [3]. - A cash dividend of $0.24 per share was declared and paid to common stockholders, with preferred stockholders receiving a quarterly dividend of $0.3906 per share [3]. Share Repurchase and Capital Management - The company repurchased 1,117,024 shares of common stock for a total of $9.3 million, increasing book value per common share by $0.04 [3]. - A new share repurchase program was approved, allowing for the repurchase of up to $25.0 million of common stock [3]. Loan Activity - In the third quarter, the company originated $279.2 million in total loan commitments, maintaining a loan portfolio that is 100% performing [2][3]. - The weighted average interest rate for newly originated loans was Term SOFR plus 3.22%, with a loan-to-value ratio of 64.9% [3]. - Loan repayments totaled $415.8 million, with the majority coming from multifamily and hotel properties [3]. Liquidity and Financial Position - The company ended the quarter with $216.4 million in near-term liquidity, including $77.2 million in cash available for investment [3]. - An allowance for credit losses was recorded at $66.1 million, a decrease from the previous quarter [3]. Subsequent Events - The company closed three first mortgage loans with total commitments of $196.5 million and announced the pricing of a $1.1 billion managed Commercial Real Estate Collateralized Loan Obligation [11].

Core Insights - The article discusses the investment perspective of Joseph Jones, focusing on dividend growth investment strategies [1] Group 1: Company Insights - Joseph Jones is a professor at The University of Southern Mississippi, specializing in portfolio construction [1] Group 2: Industry Insights - The insights expressed in the research are solely those of Joseph Jones and may not represent the views of his employer [1]

Core Insights - TPG is a global alternative asset firm focusing on private equity, real estate, and public market investments, with a current stock price of $56.52 and a price target set by Morgan Stanley at $63, indicating a potential increase of approximately 11.47% [1][6] Company Overview - TPG has a market capitalization of approximately $21.03 billion, positioning it as a significant player in the financial sector [4] - The company's stock price has shown volatility, with a high of $72.98 and a low of $37.52 over the past year [3][6] Recent Developments - TPG, in collaboration with Blackstone, announced a significant acquisition of Hologic for up to $18.3 billion, which involves purchasing all outstanding shares at $76 each in cash [2][5] - This acquisition marks a strategic move into the healthcare sector, aligning with TPG's interest in diversifying and strengthening its investment portfolio [2][5] Market Activity - TPG's stock price currently stands at $56.58, reflecting a 1.35% increase or $0.76, with today's trading volume at 343,613 shares, indicating active investor interest [3][4]

Core Viewpoint - Private equity firms Blackstone and TPG are acquiring Hologic for over $13 billion, taking the company private with a share price of up to $79, representing a 46% premium from late May [1][2]. Deal Structure - The acquisition includes $76 in cash per share, with additional payments contingent on revenue goals from Hologic's breast health business, bringing the total deal value to $18.3 billion when factoring in Hologic's $2.2 billion in cash and short-term investments and $2.5 billion in debt [2]. Regulatory and Approval Status - The deal requires approval from regulators and Hologic shareholders, but has already received unanimous approval from Hologic's board. The transaction is expected to close in the first half of next year [3]. Market Reaction - Following the announcement, Hologic shares increased nearly 4% to $74.62, while broader market indexes showed mixed performance [5]. Post-Transaction Details - After the acquisition, Hologic will be delisted from the Nasdaq stock exchange but will retain its name and headquarters in Marlborough, Massachusetts [5].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the proposed sale of Hologic, Inc. to funds managed by Blackstone and TPG for Hologic shareholders [1] Transaction Details - Hologic shareholders are set to receive $76.00 per share in cash [1] - Additionally, shareholders will receive a non-tradable contingent value right to receive up to $3.00 per share, payable in two installments of up to $1.50 each [1]

Core Viewpoint - Hologic has reached a final acquisition agreement with Blackstone and TPG, valuing the company at up to $79 per share and an enterprise value of up to $18.3 billion [1] Group 1: Acquisition Details - Blackstone and TPG will acquire all outstanding shares of Hologic at $76 per share in cash [1] - An additional non-tradable contingent value right allows shareholders to receive up to $3 per share in two installments, contingent on meeting specific revenue targets in Hologic's breast health business for fiscal years 2026 and 2027 [1]

Core Viewpoint - Blackstone and TPG have agreed to acquire all outstanding shares of a women's health company for $76 per share in cash [1] Company Summary - The acquisition involves a cash payment of $76 for each share of the women's health company [1]

Core Viewpoint - Blackstone and TPG are set to acquire Hologic for up to $18.3 billion, marking a significant healthcare take-private transaction in 2023 [1] Group 1: Acquisition Details - The acquisition price is $76 per share in cash, representing a nearly 6% premium over Hologic's last closing price [1] - Shareholders may receive a non-tradable right to an additional $3 per share, contingent on achieving specific global revenue targets for the breast health business in fiscal years 2026 and 2027, potentially raising the total payout to $79 per share [2] Group 2: Company Performance - Hologic specializes in women's health diagnostics, including breast and cervical cancer screening and infectious disease testing [2] - The company has experienced steady growth in its molecular diagnostics business but has indicated ongoing weakness in the breast health segment [3] Group 3: Transaction Timeline - The deal is anticipated to close in the first half of 2026 [3]

Core Viewpoint - Blackstone and TPG have reached an agreement to acquire Hologic, a medical diagnostics firm, in a deal valued at up to $18.3 billion [1] Company Summary - The acquisition involves two major investment firms, Blackstone and TPG, indicating strong interest in the medical diagnostics sector [1] - Hologic is positioned within the healthcare industry, specifically focusing on medical diagnostics, which is a critical area for investment given the ongoing demand for healthcare solutions [1] Financial Summary - The total deal value for the acquisition of Hologic is up to $18.3 billion, highlighting the significant financial commitment from Blackstone and TPG [1]